Bristol Myers Says IZA-BREN Cut Progression or Death Risk 59% in Phase 3
Bristol Myers said its breast cancer drug IZA-BREN reduced the risk of progression or death by 59% in a Phase 3 study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.